Analyst Activity – BMO Capital Markets Reiterates Hold on Biogen (NASDAQ:BIIB)

ME Staff
-
0

Analyst Ratings For Biogen (NASDAQ:BIIB)

Today, BMO Capital Markets reiterated its Hold rating on Biogen (NASDAQ:BIIB) with a price target of $318.00.

There are 11 hold ratings, 12 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Biogen (NASDAQ:BIIB) is Buy (Score: 2.58) with a consensus target price of $327.76 per share, a potential 15.98% upside.

Some recent analyst ratings include

  • 7/18/2017-BMO Capital Markets Reiterated Rating of Hold.
  • 7/11/2017-Jefferies Group LLC Reiterated Rating of Hold .
  • 7/10/2017-Morgan Stanley Reiterated Rating of Equal Weight.
  • 7/3/2017-Cowen and Company Reiterated Rating of Outperform.
  • 6/26/2017-William Blair Reiterated Rating of Outperform.
  • 6/23/2017-Deutsche Bank AG initiated coverage with a Buy rating.

Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.32% and institutional ownership of 87.47%.

  • On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04. View SEC Filing
  • On 5/1/2017 Michel Vounatsos, CEO, bought 1,402 with an average share price of $271.35 per share and the total transaction amounting to $380,432.70. View SEC Filing
  • On 4/27/2017 Alexander J. Denner, Director, bought 73,858 with an average share price of $278.50 per share and the total transaction amounting to $20,569,453.00. View SEC Filing
  • On 4/25/2017 Paul J Clancy, VP, sold 9,892 with an average share price of $290.00 per share and the total transaction amounting to $2,868,680.00. View SEC Filing
  • On 4/3/2017 Alfred Sandrock, CMO, sold 1,981 with an average share price of $274.08 per share and the total transaction amounting to $542,952.48. View SEC Filing
  • On 3/13/2017 Paul J Clancy, VP, sold 9,891 with an average share price of $291.55 per share and the total transaction amounting to $2,883,721.05. View SEC Filing
  • On 2/27/2017 Michel Vounatsos, CEO, bought 1,333 with an average share price of $285.39 per share and the total transaction amounting to $380,424.87. View SEC Filing

Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 282.60 down -0.05 -0.02% with 1,122,506 shares trading hands.